Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Minot Light Capital Partners Tom Wetherald and Eddie Reilly | “Elutia is a micro-cap medical technology enterprise developing proprietary drug-eluting biomatrices engineered to prevent surgical-site infections, currently sized as a roughly 0.6% position in the fund. Minot Light initiated a speculative bullish position, identifying an asymmetric risk-reward setup where the prevailing equity price trades at a discount to net cash. The company's core product candidate delivers targeted antibiotics locally following reconstructive breast surgeries to eliminate typical 15% to 20% post-operative infection risks. Because Elutia intends to price its differentiated product at near price-parity with traditional non-drug-eluting matrices, hospital value-analysis committees face a compelling economic value proposition via reduced revision surgery costs. The underlying proprietary platform was previously de-risked when Boston Scientific acquired Elutia's similarly engineered BioEnvelope for $88 million. Financial downside is heavily buffered by $40 million in net cash ($0.84 per share), which exceeds the $0.75 market price and funds operations through commercial launch. The primary catalyst is anticipated FDA regulatory clearance and commercial commercialization slated for late 2027 into a $1 billion breast reconstruction TAM, which could catalyze upside toward $10.00 per share. Key risks include binary regulatory delays or rejection by the FDA, clinical development hurdles, and potential balance sheet dilution if cash burn outpaces timelines.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.